- Home
- ETNB vs AZTA Comparison
ETNB vs AZTA Comparison
Compare ETNB & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- AZTA
- Stock Information
- Founded
- ETNB 2018
- AZTA 1978
- Country
- ETNB United States
- AZTA United States
- Employees
- ETNB N/A
- AZTA N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- AZTA Industrial Machinery/Components
- Sector
- ETNB Health Care
- AZTA Technology
- Exchange
- ETNB Nasdaq
- AZTA Nasdaq
- Market Cap
- ETNB 1.5B
- AZTA 1.4B
- IPO Year
- ETNB 2019
- AZTA 1995
- Fundamental
- Price
- ETNB $9.23
- AZTA $30.39
- Analyst Decision
- ETNB Strong Buy
- AZTA Buy
- Analyst Count
- ETNB 8
- AZTA 4
- Target Price
- ETNB $26.29
- AZTA $42.00
- AVG Volume (30 Days)
- ETNB 1.6M
- AZTA 747.6K
- Earning Date
- ETNB 08-07-2025
- AZTA 08-05-2025
- Dividend Yield
- ETNB N/A
- AZTA N/A
- EPS Growth
- ETNB N/A
- AZTA N/A
- EPS
- ETNB N/A
- AZTA N/A
- Revenue
- ETNB N/A
- AZTA $668,821,000.00
- Revenue This Year
- ETNB N/A
- AZTA N/A
- Revenue Next Year
- ETNB N/A
- AZTA $4.74
- P/E Ratio
- ETNB N/A
- AZTA N/A
- Revenue Growth
- ETNB N/A
- AZTA 12.46
- 52 Week Low
- ETNB $4.16
- AZTA $23.91
- 52 Week High
- ETNB $11.84
- AZTA $55.64
- Technical
- Relative Strength Index (RSI)
- ETNB 45.00
- AZTA 47.79
- Support Level
- ETNB $8.95
- AZTA $27.95
- Resistance Level
- ETNB $9.50
- AZTA $32.26
- Average True Range (ATR)
- ETNB 0.54
- AZTA 1.63
- MACD
- ETNB -0.03
- AZTA -0.12
- Stochastic Oscillator
- ETNB 42.60
- AZTA 46.73
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.